Metabolic and bariatric surgery for obesity in Prader Willi syndrome: systematic review and meta-analysis.

Obesity is the leading cause of morbidity and mortality in patients with Prader-Willi Syndrome (PWS). Our objective was to compare changes in body mass index (BMI) after metabolic and bariatric surgery (MBS) for the treatment of obesity (BMI ≥35 kg/m2) in PWS. A systematic review of MBS in PWS was performed using PubMed, Embase, and Cochrane Central, identifying 254 citations. Sixty-seven patients from 22 articles met criteria for inclusion in the meta-analysis. Patients were organized into 3 groups: laparoscopic sleeve gastrectomy (LSG), gastric bypass (GB), and biliopancreatic diversion (BPD). No mortality within 1 year was reported in any of the 3 groups after a primary MBS operation. All groups experienced a significant decrease in BMI at 1 year with a mean reduction in BMI of 14.7 kg/m2 (P < .001). The LSG groups (n = 26) showed significant change from baseline in years 1, 2, and 3 (P value at year 3 = .002) but did not show significance in years 5, 7, and 10. The GB group (n = 10) showed a significant reduction in BMI of 12.1 kg/m2 in the first 2 years (P = .001). The BPD group (n = 28) had a significant reduction in BMI through 7 years with an average reduction of 10.7 kg/m2 (P = .02) at year 7. Individuals with PWS who underwent MBS had significant BMI reduction sustained in the LSG, GB, and BPD groups for 3, 2, and 7 years, respectively. No deaths within 1 year of these primary MBS operations were reported in this study or any other publication.

Attrition Rates Among African American Patients with Obesity Seeking Bariatric Surgery: a High-Volume Single Center Analysis.

Despite the greater prevalence of obesity, African American (AA) adults represent a minority of bariatric surgery patients. The aim of this study was to determine variables associated with attrition among AA patients seeking bariatric surgery. We performed a retrospective analysis of a consecutive series of AA patients with obesity referred for surgery and who initiated the preoperative work-up as per insurance requirements. The sample was then divided between those undergoing surgery and those who did not receive surgery. The multivariable logistic regression analysis showed that male patients (OR 0.53 95% CI 0.28-0.98) and those with public insurance (OR 0.56, 95% CI 0.37 - 0.83) were significantly less likely to undergo surgery. The use of telehealth was strongly associated with receiving surgery (OR 3.53, 95% CI 2.36 - 5.29). Our results might help developing targeted strategies to reduce attrition rates among AA patients with obesity seeking bariatric surgery.

Estratificação de risco dos pacientes na fila de espera para cirurgia bariátrica no Hospital do Servidor Público Municipal para elaboração de pontuação do Protocolo de Gravidade SOS (Score de Obesidade do Servidor) / Risk stratification of patients on the waiting list for bariatric surgery at the Hospital do Servidor Público Municipal to prepare a score for the SOS Severity Protocol (Server Obesity Score)

A obesidade é confirmada como um dos principais fatores de risco de doenças cardiovasculares, diabetes mellitus e doença renal crônica, entre outros. Na projeção para os próximos 12 anos, o Brasil terá 41% de sua população adulta com obesidade, segundo a nova edição do Atlas Mundial da Obesidade 2023. O número é confirmado para 2035 a partir das tendências projetadas na prevalência de obesidade. Para os adultos, o crescimento será de 2,8% por ano, enquanto nas crianças, fator mais preocupante, o crescimento anual será de 4,4%. O objetivo deste estudo é a estratificação de risco dos pacientes que estão aguardando cirurgia bariátrica pelo HSPM (Hospital do Servidor Público Municipal), através do protocolo SOS (Score de Obesidade do Servidor), ao definir critérios de gravidade e priorização desses pacientes, correlacionando a obesidade ao grau de disfunções orgânicas dos mesmos. Em nosso serviço o tempo na fila de espera para a cirurgia bariátrica gira em torno de 6 a 7 anos, para todos os pacientes, não levando em consideração as comorbidades e riscos destes indivíduos, e no Brasil não há até hoje nenhum protocolo de priorização por comorbidades descrito para a cirurgia bariátrica. Foi realizada a estratificação de gravidade dos pacientes que aguardam pela cirurgia bariátrica no HSPM, com elaboração de pontuação de risco alto (maior ou igual que cinco pontos: prioridade vermelha), médio (3 a 4 pontos: prioridade amarela) e baixo (0 a 2 pontos: prioridade verde), através do protocolo SOS (Score de Obesidade do Servidor). Palavras-chave: Cirurgia bariátrica. Obesidade. Listas de espera. Priorização. Manejo de Obesidade.

Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity.

Importance: Obesity increases the incidence and mortality from some types of cancer, but it remains uncertain whether intentional weight loss can decrease this risk. Objective: To investigate whether bariatric surgery is associated with lower cancer risk and mortality in patients with obesity. Design, Setting, and Participants: In the SPLENDID (Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death) matched cohort study, adult patients with a body mass index of 35 or greater who underwent bariatric surgery at a US health system between 2004 and 2017 were included. Patients who underwent bariatric surgery were matched 1:5 to patients who did not undergo surgery for their obesity, resulting in a total of 30 318 patients. Follow-up ended in February 2021. Exposures: Bariatric surgery (n = 5053), including Roux-en-Y gastric bypass and sleeve gastrectomy, vs nonsurgical care (n = 25 265). Main Outcomes and Measures: Multivariable Cox regression analysis estimated time to incident obesity-associated cancer (a composite of 13 cancer types as the primary end point) and cancer-related mortality. Results: The study included 30 318 patients (median age, 46 years; median body mass index, 45; 77% female; and 73% White) with a median follow-up of 6.1 years (IQR, 3.8-8.9 years). The mean between-group difference in body weight at 10 years was 24.8 kg (95% CI, 24.6-25.1 kg) or a 19.2% (95% CI, 19.1%-19.4%) greater weight loss in the bariatric surgery group. During follow-up, 96 patients in the bariatric surgery group and 780 patients in the nonsurgical control group had an incident obesity-associated cancer (incidence rate of 3.0 events vs 4.6 events, respectively, per 1000 person-years). The cumulative incidence of the primary end point at 10 years was 2.9% (95% CI, 2.2%-3.6%) in the bariatric surgery group and 4.9% (95% CI, 4.5%-5.3%) in the nonsurgical control group (absolute risk difference, 2.0% [95% CI, 1.2%-2.7%]; adjusted hazard ratio, 0.68 [95% CI, 0.53-0.87], P = .002). Cancer-related mortality occurred in 21 patients in the bariatric surgery group and 205 patients in the nonsurgical control group (incidence rate of 0.6 events vs 1.2 events, respectively, per 1000 person-years). The cumulative incidence of cancer-related mortality at 10 years was 0.8% (95% CI, 0.4%-1.2%) in the bariatric surgery group and 1.4% (95% CI, 1.1%-1.6%) in the nonsurgical control group (absolute risk difference, 0.6% [95% CI, 0.1%-1.0%]; adjusted hazard ratio, 0.52 [95% CI, 0.31-0.88], P = .01). Conclusions and Relevance: Among adults with obesity, bariatric surgery compared with no surgery was associated with a significantly lower incidence of obesity-associated cancer and cancer-related mortality.

Consulta en servicio de urgencia y reingreso hospitalario después de una cirugía bariátrica primaria / Emergency department visit and Hospital Readmission after Primary Bariatric Surgery

Resumen Introducción: Las consultas en el servicio de urgencia (CU) y el reingreso (RI) hospitalario después de una cirugía bariátrica (CB) son importantes indicadores de calidad y seguridad. Sin embargo, existe escasa información de estos indicadores en nuestro medio nacional. En este trabajo analizamos las CU y RI de pacientes sometidos a una CB primaria en un centro universitario de alto volumen, y buscamos variables asociadas a estos indicadores. Materiales y Método: Estudio observacional retrospectivo que incluyó a todos los pacientes sometidos a bypass gástrico (BPG) o gastrectomía en manga (GM) laparoscópica primaria realizados de forma consecutiva en nuestra institución durante el período 2006-2007 y 2012-2013. Utilizando nuestros registros clínicos y base de seguimiento prospectivo, identificamos aquellos pacientes con CU o RI en nuestro hospital durante los primeros 30 días después del alta. Resultados: Se incluyeron 1.146 CB primarias, 53% (n = 613) fueron BPG y 47% (n = 533) GM. Un 8,03% (n = 92) de los pacientes tuvo al menos una CU y un 3,7% (n = 42) un RI. Las variables independientes asociadas tanto a CU como RI fueron el tiempo operatorio e índice de masa corporal (IMC) preoperatorio. No se encontró asociación estadística, en el periodo estudiado, para el tipo de CB realizada con la CU ni con el RI. Conclusión: Existe una baja proporción de pacientes que requieren CU y RI posterior a la CB, lo que demuestra la seguridad de estas intervenciones.

Introduction: Emergency department visits (EDV) and hospital readmission (HR) after bariatric surgery (BS) are important indicators of quality and safety in surgery, however there is little information on their characteristics in our national environment. Aim: In this work we analyze EDV and HR in patients undergoing a primary BS in a high-volume university center, and identify variables that could be associated with these indicators. Materials and Method: A retrospective observational study where we identified all patients undergoing Roux-in-Y gastric bypass (RYGBP) or primary laparoscopic sleeve gastrectomy (SG) performed consecutively at our institution during the period 2006-2007 and 2012-2013. Using our clinical records and prospective follow-up database, we identify those patients with EDV and/or HR in our hospital during the first 30 days after discharge. Results: 1146 primary BS were included, of these 53% (n = 613) were RYGBP and 47% (n = 533) SG. 8,03% (n = 92) of the patients had at least one EDV, of these 3,7% (n = 42) had an HR. The independent variables associated with EDV and HR were the operative time and preoperative body mass index (BMI). No statistical association was found, in the period studied, for the type of BS performed with EDV or HR. Conclusion: There is a low proportion of patients who require EDV and HR after BS, which demonstrates the safety of these interventions.

Cortisol/DHEA ratio in morbidly obese patients before and after bariatric surgery: Relation to metabolic parameters and cardiovascular performance.

INTRODUCTION: Bariatric surgery (BS) is the most effective therapy for morbid obesity. Cortisol and DHEA are steroid hormones with opposing effects, thus using Cortisol/DHEA ratio (C/D) rather than the use of either hormone alone has been found to predict health outcomes more reliably. It was interesting to study C/D as an indicator of favorable metabolic and cardiovascular outcomes after BS. OBJECTIVE: To assess C/D in morbidly obese patients before and after BS in relation to metabolic parameters and cardiovascular performance. PATIENTS AND METHODS: Forty morbidly obese patients were followed prospectively for 1 year after BS. Fasting blood glucose (FBG), fasting insulin (FI), C/D, lipid profile, high-sensitive CRP (hs-CRP), and echocardiography were done before BS and at 3 months and 1 year post BS. RESULTS: A total of 40 morbidly obese patients undergone sleeve gastrectomy. Blood pressure, FBG, FI, hs-CRP, C/D were significantly decreased after BS (p < 0.001). At 1 year post BS; significant reduction in left ventricular posterior wall thickness (LVPW) (p < 0.001), left ventricular mass (LVM) (p = 0.003), relative wall thickness (RWT) (p < 0.001) with a significant improvement in early diastolic velocity (E) (p < 0.001), early diastolic velocity/late diastolic velocity (E/A) (p = 0.01). After BS; C/D significantly positively correlated with FBG (p = 0.019), hs-CRP (p = 0.008), interventricular septum thickness (IVS) (p = 0.028), LVPW (p = 0.028), relative wall thickness (RWT) (p = 0.022), early diastolic velocity /early diastolic velocity (E') measured by pulsed tissue Doppler imaging (E/E') (p = 0.001), and significantly negatively correlated with E' (p = 0.032). C/D was the single significant independent variable affecting E' and E/E' post BS. CONCLUSION: C/D can be used as a surrogate marker of the improved FBG and the resolution of inflammation post BS. C/D is an independent predictor of diastolic function improvement post BS.

Weight-loss thresholds after bariatric surgery and cardiovascular outcomes: more is better.

BACKGROUND/OBJECTIVES: Whether the extent of weight loss (WL) modulates bariatric surgery (BS) cardiovascular benefits has scarcely been assessed. Several WL thresholds have been commonly used to classify BS patients as good or poor responders without a proven clinical relevance. We examined the relationship between the magnitude of WL after BS and post-surgery major adverse cardiovascular-event (MACE) incidence. We also compared the performance of three different insufficient weight-loss (IWL) criteria for their association with MACE. SUBJECTS AND METHODS: All individuals who underwent a primary Roux-en Y gastric bypass (RYGB) or sleeve gastrectomy (SG) in our institution at least six years before data analysis (12/2020) were included in the study. Data on MACE were available in 1638 of 1700 participants (96.4%). Proportional-hazard Cox analyses were performed to ascertain the association between MACE, WL, and the three IWL criteria. IWL was defined as: <50% excess weight loss (<50% EWL), <20% total body-weight loss (<20% TBWL), and -1 standard deviation of alterable weight-loss percentage (<1 SD% AWL). RESULTS: During a mean follow-up of 10.2 ± 2.8 years, 86 participants experienced a first post-surgery MACE. Higher WL at one year (HR: 0.77 (95% CI: 0.61-0.98)) and 5 years (HR: 0.63 (95% CI: 0.42-0.92)) was related to a lower incidence of MACE. All short-term criteria for defining IWL were similarly associated with MACE, yet <1 SD% AWL identified more at-risk subjects. Five-year TBWL < 20% and 5-year <1 SD-AWL% were significantly associated with a higher risk for CV events. TBWL < 20% identified more subjects at risk. CONCLUSIONS: The extent of WL is closely related to long-term MACE incidence. Patients who lost -1SD% AWL at one year or <20% TBWL at five years may be considered poor responders.

Consistent gut bacterial and short-chain fatty acid signatures in hypoabsorptive bariatric surgeries correlate with metabolic benefits in rats.

OBJECTIVE: The study aimed at comparing how changes in the gut microbiota are associated to the beneficial effects of the most clinically efficient hypoabsorptive bariatric procedures, namely Roux-en-Y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD-DS) and single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). METHODS: Diet-induced obese (DIO) male Wistar rats were divided into seven groups. In addition to the groups subjected to RYGB, BPD-DS and SADI-S, the following four control groups were included: SHAM-operated rats fed a high-fat diet (SHAM HF), SHAM fed a low-fat diet (SHAM LF), SHAM HF-pair-weighed to BPD-DS (SHAM HF-PW) and sleeve-gastrectomy (SG) rats. Body weight, food intake, glucose tolerance, insulin sensitivity/resistance, and L-cell secretion were assessed. The gut microbiota (16 S ribosomal RNA gene sequencing) as well as the fecal and cæcal contents of short-chain fatty acids (SCFAs) were also analyzed prior to, and after the surgeries. RESULTS: The present study demonstrates the beneficial effect of RYGB, BPD-DS and SADI-S on fat mass gain and glucose metabolism in DIO rats. These benefits were proportional to the effect of the surgeries on food digestibility (BPD-DS > SADI-S > RYGB). Notably, hypoabsorptive surgeries led to consonant microbial signatures characterized by decreased abundance of the Ruminococcaceae (Oscillospira and Ruminococcus), Oscillospiraceae (Oscillibacter) and Christensenellaceae, and increased abundance of the Clostridiaceae (Clostridium), Sutterellaceae (Sutterella) and Enterobacteriaceae. The gut bacteria following hypoabsorptive surgeries were associated with higher fecal levels of propionate, butyrate, isobutyrate and isovalerate. Increases in the fecal SCFAs were in turn positively and strongly correlated with the levels of peptide tyrosine-tyrosine (PYY) and with the beneficial effects of the surgery. CONCLUSION: The present study emphasizes the consistency with which the three major hypoabsorptive bariatric procedures RYGB, BPD-DS and SADI-S create a gut microbial environment capable of producing a SCFA profile favorable to the secretion of PYY and to beneficial metabolic effects.

Bariatric surgery versus medical treatment in mildly obese patients with type 2 diabetes mellitus in Japan: Propensity score-matched analysis on real-world data.

AIMS/INTRODUCTION: To compare glycemic control 1 year after treatment in patients with mildly obese (body mass index 27.5-34.9 kg/m2 ) type 2 diabetes mellitus who underwent bariatric surgery (BS) to those who received medical treatment (MT) in Japan. MATERIALS AND METHODS: A retrospective study using real-world data was carried out in electronic medical records from a tertiary care hospital and in the Japanese Medical Data Center Inc. claim database from 2008 to 2019. Each patient was propensity score-matched between the BS and the MT group by age, sex, body mass index, glycated hemoglobin and type 2 diabetes mellitus duration, and compared from the index date to the 1 year post-index. RESULTS: The study included 78 patients in the BS group and 238 patients in the MT group. The mean body mass index in the BS and the MT group was 32.1 and 32.0 kg/m2 , respectively. In the BS group, the patients underwent either laparoscopic sleeve gastrectomy with or without duodenojejunal bypass. The diabetes remission rate (glycated hemoglobin <6.5% without diabetes medication) at 1 year was 59.0% in the BS group and 0.4% in the MT group (P < 0.0001). Optimal glycemic control of glycated hemoglobin <7.0% was achieved in 75.6% in the BS group and in 29.0% in the MT group (P < 0.0001). The median monthly drug costs for metabolic syndrome decreased from $US126.5 (at baseline) to $US0.0 (at 1 year) in the BS group, whereas it increased from $US52.4 to $US58.3 in the MT group. CONCLUSIONS: BS for mildly obese patients with type 2 diabetes mellitus is more clinically- and cost-effective than MT in Japan.

Association of prenatal substance use disorders with pregnancy and birth outcomes following bariatric surgery.

BACKGROUND/OBJECTIVES: While an increased risk for substance use disorders (SUD) and also for several adverse pregnancy and birth outcomes in patients who have undergone bariatric surgery have been well documented when considered separately, an association between these important risk factors has not been investigated. This study explored the potential dependence of these two bariatric surgery-related risks. SUBJECTS/METHODS: This study was a retrospective cohort study with adult women (18-45) who underwent bariatric surgery between 1996 and 2016 and who gave birth after surgery between 1996 and 2018. The study population consisted of 1849 post-bariatric surgery women with 3010 reported post-surgical births. Subjects with post-surgical, prenatal SUD were identified based on diagnosis codes extracted within the 10 months prior to delivery. Using random-effects logistic regression with retrospective cohort data, preterm birth, low birth weight, macrosomia, Caesarian delivery, congenital anomalies, and neonatal intensive care unit admission were considered as outcomes. RESULTS: About 10% (n = 289) of women had an SUD diagnosis within 10 months prior to child delivery. Women with SUD during pregnancy had significantly more pregnancy and birth complications compared to women without SUD: preterm birth (OR = 2.08, p = 0.03, 95% CI: 1.07-4.03), low birth weight (OR = 3.41, p < 0.01, 95% CI: 1.99-5.84), Caesarian delivery (OR = 9.71, p < 0.01, 95% CI: 2.69-35.05), and neonatal intensive care unit admission (OR = 3.87, p < 0.01, 95% CI: 2.04-7.34). Women with SUD had lower risk for macrosomia than women without SUD (OR = 0.07, p = 0.02, 95% CI: 0.01-0.70). CONCLUSION: Results from this study demonstrated that post-bariatric surgery women who had SUD during pregnancy had significantly more pregnancy- and birth-related complications than post-surgery pregnant women without SUD, despite the reduction in macrosomia. Where possible, greater prenatal surveillance of post-surgery women with SUD should be considered.

Análise custo-efetividade da cirurgia bariátrica para combate à obesidade moderada e severa no contexto do Sistema Único de Saúde / Cost-effectiveness analysis of bariatric surgery to tackle moderate and severe obesity in the context of the Brazilian Unified Health System

Introdução: O excesso de peso é um dos principais fatores de risco para mortalidade e carga global de doenças no mundo. No Brasil, o incremento na prevalência de sobrepeso e obesidade constitui um desafio em saúde pública ao longo das últimas três décadas, acarretando uma grande e crescente pressão nos custos em saúde para seu tratamento. Objetivos: O objetivo da tese foi conduzir uma revisão sistemática com meta-análise da literatura científica sobre avaliação econômica da cirurgia bariátrica em diferentes países, destacando custos e desfechos em saúde da intervenção em curto, médio e longo prazo; assim como investigar custo e efetividade de diferentes estratégias de abordagem da cirurgia bariátrica como intervenção para combate à obesidade moderada a severa em uma coorte de pacientes do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP). Metodologia: O estudo foi conduzido em duas etapas: revisão sistemática e meta-análise da literatura e avaliação dos custos e da efetividade do tratamento de obesidade moderada a severa por meio de cirurgia bariátrica. A revisão sistemática com meta-análise buscou estabelecer nível de qualidade das evidências científicas sobre associação entre custos do tratamento da obesidade por meio de cirurgia bariátrica e desfechos em saúde relacionados à prevalência de doenças crônicas não transmissíveis (DCNT). A avaliação dos custos e da efetividade da cirurgia bariátrica foi baseada em coleta de dados clínicos e sociodemográficos junto aos bancos de dados de prontuários eletrônicos dos pacientes do Departamento de Gastroenterologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP). Foi utilizada análise de séries temporais para verificação de diferenças entre custos e desfechos em saúde pré- e pós-cirurgia bariátrica, assim como tendência ao longo do período de acompanhamento pré- e pós-cirurgia bariátrica. Resultados: A etapa de revisão sistemática e meta-análise identificou 697 artigos, sendo incluídos 50 estudos na extração e análise de dados, totalizando 15.548.697 pacientes. Dos estudos incluídos, 27 (54%) realizaram avaliação econômica completa, sendo 20 estudos de análise custo-efetividade (40%) e 7 estudos de análise custo-utilidade (14%), assim como 23 estudos de avaliações econômicas parciais com custos ou desfechos (46%). Somente 6 estudos avaliaram custo e efetividade da cirurgia bariátrica comparados ao tratamento tradicional de doenças relacionadas à obesidade e 3 estudos apresentaram comparação entre custo da cirurgia bariátrica e custo da obesidade. O custo da cirurgia bariátrica sem especificação da técnica foi apresentado em 19 estudos, correspondendo a US$ 49,419.63 ± 96,707.49 (mediana = US$ 12,661.96). O resultado da meta-análise de estudos que avaliaram custos pré- e pós-cirurgia bariátrica apontou redução de aproximadamente 70% nos custos pós-intervenção (diferença média padronizada, SMD = 1,691; p = 0,01). A análise do custo e da efetividade da cirurgia bariátrica na coorte do ICHC-FMUSP incluiu 318 pacientes que foram submetidos a cirurgia bariátrica entre 2017 e 2018 (267 mulheres = 83,9% e 51 homens = 16,1%), sendo incluídos indivíduos com dados completos de acompanhamento de 240 meses pré-cirurgia bariátrica e 24 meses pós-cirurgia bariátrica. O custo total antes da cirurgia bariátrica foi US$ 7,915.35 ± 15,426.70 e o custo total após a cirurgia bariátrica foi US$ 7,347.97 ± 23,105.05 (p = 0,326). O custo total dos procedimentos realizados por via aberta (laparotômica) foi de US$ 15,806.01 ± 17,167.89, US$ 8,477.10 ± 3,929.73 e US$ 10,054.58 ± 7,834.89 nas cirurgias gastrectomia vertical, BGA e BGYR, respectivamente (p = 0,0195 entre gastrectomia vertical e BGA). O custo total dos procedimentos realizados por via laparoscópica foi de US$ 5,589.11 ± 0.00, US$ 4,759.14 ± 0.00 e US$ 7,027.38 ± 7,719.15 nas cirurgias gastrectomia vertical, BGA e BGYR, respectivamente (p = 0,093). Após a cirurgia bariátrica, houve redução estatisticamente significativa no peso corporal e IMC (p<0,001). Conclusão: A cirurgia bariátrica apresenta elevada razão de custo-efetividade, com reversão da maioria dos marcadores de risco para doenças crônicas não transmissíveis relacionadas à obesidade no paciente adulto, contribuindo à diminuição dos custos do atendimento de pacientes no âmbito do sistema público de saúde em médio e longo prazos.

Introduction: Excess body weight comprises one of the main risk factors for mortality and global burden of disease worldwide. In Brazil, the increase in prevalence of overweight and obesity represents a challenge in public health throughout the last three decades, caucusing an increasing burden of cost on health services. Objectives: The objective of the dissertation was to conduct a systematic review with meta-analysis of scientific literature on economic assessment of bariatric surgery in diverse countries, highlighting health care costs and health outcomes of the intervention in short-, medium-, and long-term; and to investigate cost and effectiveness of diverse strategies of bariatric surgery to tackle moderate to severe obesity in a cohort of patients of the Clinics Hospital at the School of Medicine of the University of Sao Paulo (HC-FMUSP). Methodology: The study was conducted in two stages: systematic review and meta-analysis of the literature, and assessment of costs and effectiveness of treatment of moderate to severe obesity through bariatric surgery. The systematic review with meta-analysis focused on the level of scientific evidence on the association between health care costs for treatment of obesity through bariatric surgery and health outcomes related to the prevalence of chronic non communicable diseases (NCD). The assessment of costs and effectiveness of bariatric surgery was based on data collection of clinical and sociodemographic information in electronic medical records of patients from the Department of Gastroenterology of the Clinics Hospital at the School of Medicine of the University of Sao Paulo (HC-FMUSP). A time-series analysis was performed to verify differences between health care costs and health outcomes pre- and post-bariatric surgery, and trends throughout follow-up before and after the surgery. Results: The systematic review and meta-analysis stage identified 697 studies, being 50 studies included in the data extraction and analysis, corresponding to 6,034,589 patients. Among the studies included, 27 (54%) conducted a complete economic assessment, being 20 cost-effectiveness studies (40%) and 7 cost-utility studies (14%), and 23 partial economic assessment studies with costs and outcomes (46%). Only 6 studies assessed cost and effectiveness of bariatric surgery compared to traditional treatment of diseases related to obesity and 3 studies presented comparison between costs of bariatric surgery and costs due to obesity. The cost of bariatric surgery without indication of the surgical technique was presented in 19 studies, corresponding to US$ 49,419.63 ± 96,707.49 (median = US$ 12.661,96). The meta-analysis of the studies assessing costs pre- and post-bariatric surgery indicated reduction of approximately 70% in post-intervention costs (standard mean difference, SMD = 1,691; p = 0,01). The analysis of costs and effectiveness of bariatric surgery in the ICHC_FMUSP cohort included 318 patients who underwent bariatric surgery between 2017 and 2018 (267 women = 83.9% and 51 men = 16.1%), being included individuals with complete data on follow-up of 240 months pre-surgery and 24 months post-surgery. The total cost before bariatric surgery was US$ 7,915.35 ± 15,426.70 and the total cost after bariatric surgery was US$ 7,347.97 ± 23,105.05 (p = 0.326). The total cost of open procedures (laparotomy) was US$ 15,806.01 ± 17,167.89, US$ 8,477.10 ± 3,929.73 and US$ 10,054.58 ± 7,834.89 in surgeries of vertical gastrectomy, BGA and BGYR, respectively (p = 0.0195 between vertical gastrectomy and BGA). The total cost of procedures conducted through laparoscopy was US$ 5,589.11 ± 0.00, US$ 4,759.14 ± 0.00 and US$ 7,027.38 ± 7,719.15 in vertical gastrectomy, BGA and BGYR, respectively (p = 0.093). After bariatric surgery, there was statistically significant reduction in body weight and BMI (p<0.001). Conclusion: The bariatric surgery presents high cost-effectiveness ratio, with reversion in trends of the majority of risk factors for chronic non communicable diseases related to obesity in adult patients, contributing to the decrease in health care costs of patients in the public health system in the medium and long run.

Cardiorenal outcomes in eligible patients referred for bariatric surgery.

OBJECTIVE: Bariatric surgery is associated with reduced atherosclerotic cardiovascular disease (CVD) and heart failure hospitalization in people with type 2 diabetes (T2D) and those with prior CVD. Most patients undergoing bariatric surgery do not have T2D or CVD. Many otherwise eligible patients do not have surgery because of self-exclusion. Clinical outcomes in these groups are less established. METHODS: This study retrospectively assessed cardiorenal outcomes in 8,568 patients after acceptance of referral for surgery. RESULTS: A total of 63.8% patients did not undergo surgery. After multivariate adjustment for sex, age, BMI, income quintile, distance from hospital, hypertension, T2D, and CVD, hazard ratios (HR) for the primary (incident myocardial infarction, stroke, heart failure hospitalization, and death; HR = 0.52, 95% CI: 0.4-0.66) and secondary CVD outcomes (primary outcomes and coronary/carotid revascularization; HR = 0.53, 95% CI: 0.42-0.67) were lower in the surgery cohort. This reduction was seen in those with (primary: HR = 0.45, 95% CI: 0.32-0.63, secondary: HR = 0.47, 95% CI: 0.34-0.65) and without T2D (primary: HR = 0.61, 95% CI: 0.42-0.88, secondary: HR = 0.53, 95% CI: 0.42-0.67). Reduced kidney disease (HR = 0.46, 95% CI: 0.22-0.92) but increased liver disease hospitalization (HR = 2.5, 95% CI: 1.45-4.27) was observed with surgery. CONCLUSIONS: Non-progression to surgery associates with increased CVD despite low baseline prevalence of CVD. The cardiorenal benefits of bariatric surgery warrant confirmation in a well-powered randomized clinical trial.

A longitudinal study of the antilipolytic effect of insulin in women following bariatric surgery.

Insulin resistance of glucose utilization is fully restored following BMI normalization after bariatric surgery. We investigated if this also pertains to insulin-induced effects on fatty acid handling. Forty-three women with obesity (OB) were investigated before and 2 years after Roux-en-Y gastric by-pass when BMI was <30 kg/m2 (PO) and compared with 26 never obese women (NO). The Adipo-IR index was used as measure of insulin antilipolytic sensitivity. Changes (delta) in circulating glycerol and fatty acid levels during hyperinsulinemic euglycemic clamp represented the insulin maximum antilipolytic effect. Overall fatty acid utilization was reflected by delta fatty acids minus 3 × delta glycerol. Adipo-IR was higher in OB than in NO and PO (p < 0.0001), the latter two groups having similar values. Insulin lowered glycerol levels by about 70% in all groups, but delta glycerol was 30% larger in PO than in NO (p = 0.04). Delta adds and adds utilization were similar in all groups. We conclude that women with obesity, whose BMI is normalized after bariatric surgery, have improved maximum in vivo antilipolytic effect of insulin above expected in absolute but not relative terms as regards glycerol changes, while the handling of circulating fatty acids is changed to the normal state.

Colorectal cancer after bariatric surgery (Cric-Abs 2020): Sicob (Italian society of obesity surgery) endorsed national survey.

BACKGROUND: The published colorectal cancer (CRC) outcomes after bariatric surgery (BS) are conflicting, with some anecdotal studies reporting increased risks. The present nationwide survey CRIC-ABS 2020 (Colo-Rectal Cancer Incidence-After Bariatric Surgery-2020), endorsed by the Italian Society of Obesity Surgery (SICOB), aims to report its incidence in Italy after BS, comparing the two commonest laparoscopic procedures-Sleeve Gastrectomy (SG) and Roux-en-Y gastric bypass (GBP). METHODS: Two online questionnaires-first having 11 questions on SG/GBP frequency with a follow-up of 5-10 years, and the second containing 15 questions on CRC incidence and management, were administered to 53 referral bariatric, high volume centers. A standardized incidence ratio (SIR-a ratio of the observed number of cases to the expected number) with 95% confidence intervals (CI) was calculated along with CRC incidence risk computation for baseline characteristics. RESULTS: Data for 20,571 patients from 34 (63%) centers between 2010 and 2015 were collected, of which 14,431 had SG (70%) and 6140 GBP (30%). 22 patients (0.10%, mean age = 53 ± 12 years, 13 males), SG: 12 and GBP: 10, developed CRC after 4.3 ± 2.3 years. Overall incidence was higher among males for both groups (SG: 0.15% vs 0.05%; GBP: 0.35% vs 0.09%) and the GBP cohort having slightly older patients. The right colon was most affected (n = 13) and SIR categorized/sex had fewer values < 1, except for GBP males (SIR = 1.07). CONCLUSION: Low CRC incidence after BS at 10 years (0.10%), and no difference between procedures was seen, suggesting that BS does not trigger the neoplasm development.

Outcomes of Bariatric Surgery: Patients with Body Mass Index 60 or Greater.

INTRODUCTION: Perioperative outcomes of bariatric surgery in patients with super super obesity (SSO) (BMI ≥ 60 kg/m2) merit further investigation. METHODS: A retrospective review was conducted of patients with SSO who underwent surgery from Jun 2005 through Jun 2018 at a Metabolic and Bariatric Surgery Center of Excellence. Quantitative demographic data was summarized using descriptive statistics; categorical variables were compared using Fisher's exact test. RESULTS: Two hundred fourteen procedures were performed, of which 208 were eligible for inclusion. Majority were female (65.4%). The mean age and BMI was 43 (17-68 years) and 65.9 kg/m2 (60 95 kg/m2), respectively. Comorbidities included: obstructive sleep apnea (74%), hypertension (59%), gastro-esophageal reflux disease (43%), osteoarthritis (41%), and diabetes mellitus (30%). Surgical approach: 97 Roux-en-Y gastric bypasses (46%), 88 laparoscopic sleeve gastrectomies (42%), and 23 adjustable gastric bands (11%). Additional subset included: primary (87%), conversion (7.7%), and revision (5.3%); majority being laparoscopic (75%) and robotic (24%). Complications via Clavien-Dindo classification: one Grade I, one Grade II, three Grade IIIa, three Grade IIIb, and three Grade IVa. Thirty-day events: 11 complications (5.3%; one leak [0.5%], one deep vein thrombosis [0.5%]), six re-admissions (3%), four re-operations (2%): repair of staple-line leak, repair of incisional hernia, uterine dilation and curettage, and cholecystectomy. No mortalities occurred. Complications occurred in 14.8% of conversion/revision cases, 3.9% in primary cases (p = 0.0395) with no difference observed between laparoscopic (4.5%) and robotic (6.1%) modalities (p = 0.7051). CONCLUSION: Bariatric surgery is feasible in patients with SSO. Revision procedures may increase risk of operative complications.

Influence of polish national COVID-19 lockdown on the patient characteristics and outcomes of bariatric surgery at a high-volume center-A cohort study.

INTRODUCTION: As a result of the COVID-19 pandemic, the health care systems around the world have been overburdened resulting in significant reduction of planned surgical procedures such as bariatric surgeries. The primary aim of this study is to assess the influence of the COVID-19 national lockdown in Poland on the short-term outcomes and intraoperative course of bariatric patients in a high volume IFSO certified bariatric center. MATERIAL & METHODS: This is a retrospective analysis of 158 bariatric surgery patients, who underwent bariatric procedures either prior to or after the first national lockdown in Poland. The patients were categorized as pre-lockdown group and the post-lockdown group, each comprising of 79 patients. RESULTS: The post-lockdown group had significantly lower operative weight (105.76 vs 114.25, p = 0.012) and BMI (36.99 vs 39.93, p = 0.005) compared to pre-lockdown group. The primary length of stay was significantly longer in the post-lockdown group (3.04 vs 2.44, p = 0.001). The post-lockdown group had significantly lower mean CCI score (1.90 vs 6.67, p = 0.046) and less short-term readmissions post-discharge (0 vs 8.86, p = 0.007) than pre-lockdown group. CONCLUSION: The post-lockdown group was found to have lower body weight and BMI on the day of the operation than those operated prior to the lockdown. These findings are conflicting to previous research assessing weight changes during lockdowns. Since the qualification criteria and order of operations were similar and pre-defined for both groups, possible explanations for these findings are higher patient motivation due to COVID-19 fears and longer preparation period due to elective surgery postponement. We encourage bariatric centers globally to assess the effect of national lockdowns on the patient profiles as well as the psychological and behavioral impact on the bariatric cohort.

Potential gut-brain mechanisms behind adverse mental health outcomes of bariatric surgery.

Bariatric surgery induces sustained weight loss and metabolic benefits via notable effects on the gut-brain axis that lead to alterations in the neuroendocrine regulation of appetite and glycaemia. However, in a subset of patients, bariatric surgery is associated with adverse effects on mental health, including increased risk of suicide or self-harm as well as the emergence of depression and substance use disorders. The contributing factors behind these adverse effects are not well understood. Accumulating evidence indicates that there are important links between gut-derived hormones, microbial and bile acid profiles, and disorders of mood and substance use, which warrant further exploration in the context of changes in gut-brain signalling after bariatric surgery. Understanding the basis of these adverse effects is essential in order to optimize the health and well-being of people undergoing treatment for obesity.

30-Day morbidity and mortality of bariatric metabolic surgery in adolescence during the COVID-19 pandemic - The GENEVA study.

BACKGROUND: Metabolic and bariatric surgery (MBS) is an effective treatment for adolescents with severe obesity. OBJECTIVES: This study examined the safety of MBS in adolescents during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This was a global, multicentre and observational cohort study of MBS performed between May 01, 2020, and October 10,2020, in 68 centres from 24 countries. Data collection included in-hospital and 30-day COVID-19 and surgery-specific morbidity/mortality. RESULTS: One hundred and seventy adolescent patients (mean age: 17.75 ± 1.30 years), mostly females (n = 122, 71.8%), underwent MBS during the study period. The mean pre-operative weight and body mass index were 122.16 ± 15.92 kg and 43.7 ± 7.11 kg/m2 , respectively. Although majority of patients had pre-operative testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (n = 146; 85.9%), only 42.4% (n = 72) of the patients were asked to self-isolate pre-operatively. Two patients developed symptomatic SARS-CoV-2 infection post-operatively (1.2%). The overall complication rate was 5.3% (n = 9). There was no mortality in this cohort. CONCLUSIONS: MBS in adolescents with obesity is safe during the COVID-19 pandemic when performed within the context of local precautionary procedures (such as pre-operative testing). The 30-day morbidity rates were similar to those reported pre-pandemic. These data will help facilitate the safe re-introduction of MBS services for this group of patients.

Does bariatric surgery reduce future hospital costs? A propensity score-matched analysis using UK Biobank Study data.

OBJECTIVES: To estimate the hospital costs among persons with obesity undergoing bariatric surgery compared with those without bariatric surgery. METHODS: We analysed the UK Biobank Cohort study linked to Hospital Episode Statistics, for all adults with obesity undergoing bariatric surgery at National Health Service hospitals in England, Scotland, or Wales from 2006 to 2017. Surgery patients were matched with controls who did not have bariatric surgery using propensity scores approach with a ratio of up to 1-to-5 by year. Inverse probability of censoring weighting was used to correct for potential informative censoring. Annual and cumulative hospital costs were assessed for the surgery and control groups. RESULTS: We identified 348 surgical patients (198 gastric bypass, 73 sleeve gastrectomy, 77 gastric banding) during the study period. In total, 324 surgical patients and 1506 matched control participants were included after propensity score matching. Mean 5-year cumulative hospital costs were €11,659 for 348 surgical patients. Compared with controls, surgical patients (n = 324) had significantly higher inpatient expenditures in the surgery year (€7289 vs. €2635, P < 0.001), but lower costs in the subsequent 4 years. The 5-year cumulative costs were €11,176 for surgical patients and €8759 for controls (P = 0.001). CONCLUSIONS: Bariatric surgery significantly increased the inpatient costs in the surgery year, but was associated with decreased costs in the subsequent 4 years. However, any cost savings made up to 4 years were not enough to compensate for the initial surgical expenditure.